AIDS Therapies

GEM91 Development for AIDS Stopped

Published in Cancer Weekly, August 11th, 1997

Hybridon Inc., Cambridge, Massachusetts, announced that it has elected to stop further development of its first generation antisense drug, GEM91, based on a preliminary review of new data from an open label Phase II clinical trial of patients with advanced HIV infection.

GEM91 is a first generation (phosphorothioate) antisense oligonucleotide which targets the gag site in the HIV genome. In the Phase II trial, three of the nine subjects tested experienced decreases in platelet counts that required dose interruption. Additionally, a review of the data showed inconsistent responses to the treatment and failed to confirm the decrease in cellular viremia observed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-08-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry